HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Friedrich A. Schoendube Bruno J. Messmer Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Seipelt, R. G. Articles by Messmer, B. J. Search for Related Content PubMed PubMed Citation Articles by Seipelt, R. G. Articles by Messmer, B. J. Related Collections Valve disease Related Article

Ann Thorac Surg 2001;72:758-762
© 2001 The Society of Thoracic Surgeons

---

Original article: cardiovascular

The St. Jude "Silzone" valve: midterm results in treatment of active endocarditis

^a Department of Thoracic and Cardiovascular Surgery, University Hospital RWTH, Aachen, Germany
^b Medical Clinic I, University Hospital RWTH, Aachen, Germany

Accepted for publication April 5, 2001.

Address reprint requests to Dr Seipelt, Department of Thoracic and Cardiovascular Surgery, Universitätsklinikum RWTH Aachen, Pauwelsstr 30, G-52074 Aachen, Germany
e-mail: rseipelt{at}post.klinikum.rwth-aachen.de

Background. The Silzone-coated St. Jude Medical valve (SJM "Silzone" valve), developed to reduce prosthetic valve endocarditis (PVE), was recalled by SJM due to a higher rate of paravalvular leaks. The aim of this study was to determine the efficacy of the SJM "Silzone" valve in avoiding PVE and to evaluate the frequency of paravalvular leaks, when the valve was used exclusively for active bacterial endocarditis.

Methods. From January 1998 to December 1999, the SJM "Silzone" valve was implanted in 40 consecutive patients with active endocarditis (20 aortic, 14 mitral, and 6 both valves). Late transesophageal echocardiography was performed in 87% of survivors, and transthoracic echocardiography in the remaining 13%. Follow-up was 100%.

Results. Hospital mortality was 17.5%. Early PVE occurred in 2 of 40 patients (5%). There were two late deaths without signs of recurrent PVE. A hemodynamic relevant paravalvular leak necessitating reoperation was seen in 2 patients within 6 months after operation. The rate of a minor paravalvular leak was 13% (4 of 31 patients).

Conclusions. The SJM "Silzone" valve when implanted for active bacterial endocarditis does not give better results than other mechanical prostheses with regard to early recurrence of endocarditis. The rate of a hemodynamic relevant paravalvular leak requiring reoperation seems rather high during the early postoperative period, whereas the occurrence of minor paravalvular leaks is comparable with that of other mechanical prostheses. Routine observation, recommended for all patients with mechanical heart valves, is also sufficient for patients with the SJM "Silzone" valve.

Related Article

Invited commentary

James D. Fonger
Ann. Thorac. Surg. 2001 72: 762-763. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

				B. Mahesh, G. Angelini, M. Caputo, X. Y. Jin, and A. Bryan Prosthetic Valve Endocarditis Ann. Thorac. Surg., September 1, 2005; 80(3): 1151 - 1158. [Abstract] [Full Text] [PDF]

				J. S. Ikonomidis, J. M. Kratz, A. J. Crumbley III, M. R. Stroud, S. M. Bradley, R. M. Sade, and F. A. Crawford Jr Twenty-year experience with the St Jude Medical mechanical valve prosthesis J. Thorac. Cardiovasc. Surg., December 1, 2003; 126(6): 2022 - 2031. [Abstract] [Full Text] [PDF]